Increased intercellular adhesion molecule-1 serum concentration in cholestasis

Journal of Hepatology

Volumn 25, Issue 6, 1996, Pages 877-886

  Polzien, Frank ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Bile acid; Cholestasis; Extrahepatic; Histology; Intrahepatic; Primary biliary cirrhosis (PBC); Receiver operating characteristic curves (ROC); SICAM 1; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; BILE ACID; INTERCELLULAR ADHESION MOLECULE 1; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

EID: 0030460670     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80292-3     Document Type: Article

References (36)

1. 1. Dienstag JL. Immunological mechanisms in chronic viral hepatitis. In: Vys GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune and Stratton, 1984; 135-66.
2. 2. Vallbracht A, Gabriel P, Maier K, Hartmann F, Steinhardt HJ, Müller C, Wolf A, Mannke KH, Flemming B. Cell mediated cytotoxicity in hepatitis A virus infection. Hepatology 1986; 6: 1308-14.
3. 3. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986; 137: 1270-4.
4. 4. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-34.
5. 5. Lasky LA, Singer MS, Yednock TA, Dowbenko D, Fennie C, Rodriguez H, Nguyen T, Stachel S, Rosen SD. Cloning of a lymphocyte homing receptor reveals a lectin domain. Cell 1989; 56: 1045-55.
6. 6. Siegelmann MH, Van den Rijn M, Weissmann IL. Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains. Science 1989; 243: 1165-72.
7. 7. Dougherty GJ, Murdoch S, Hogg N. The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 1988; 18: 35-9.
8. 8. Duijvestion A, Hamann A. Mechanisms and regulation of lymphocyte migration. Immunology Today 1989; 10: 23-8.
9. 9. Lisby S, Ralfkiaer E, Rothlein R, Vejlsgaard GL. Intercellular adhesion molecule-1 (ICAM-1) expression correlated to inflammation. Br J Dermatol 1989; 120: 479-84.
10. 10. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-γ: Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-54.
11. 11. Rothlein R, Mainolfi E, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147: 3788-93.
12. 12. Volpes R, Van den Oord JJ, Desmet VJ. Immunhistochemical study of adhesion molecules in liver inflammation. Hepatology 1990; 12: 59-65.
13. 13. Adams DH, Hubscher S, Shaw J, Johnson GD, Babbs C, Rothlein R, Neuberger JM. Increased expression of ICAM-1 on bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1991; 14: 426-31.
14. 14. Adams DH, Mainolfi E, Burra P, Neuberger JM, Ayres R, Elias E, Rothlein R. Detection of circulating intercellular adhesion molecule-1 in chronic liver disease. Hepatology 1992; 16: 810-4.
15. 15. Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing chlangitis and primary biliary cirrhosis. Gut 1995; 36: 604-9.
16. 16. Kvale D, Brandtzaeg P. Immune modulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human hepatocytic cell lines. J Hepatology 1993; 17: 347-52.
17. 17. Thomson AW, Satoh S, Nüssler AK, Tamura K, Woo J, Gavaler J, Van Thiel DH. Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clin Exp Immunol 1994; 95: 83-90.
18. 18. Volpes R, Van den Oord JJ, Desmet VJ. Hepatic expression of intercellular adhesion molecule-1 (ICAM-1) in viral hepatitis-B. Hepatology 1990; 12: 148-54.
19. 19. Malizia G, Dino O, Pisa R, Caltagirone M, Giannuoli G, Di-Marco V, Aragona E, Calabese A, Raiata F, Craxi A, Pagliaro L. Expression of leucocyte adhesion molecules in the liver of patients with chronic hepatitis-B-virus infection. Gastroenterology 1991; 100: 749-55.
20. 20. Zöhrens G, Armbrust T, Pirzer U, Meyer zum Büschenfelde KH, Ramadori G. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: relationship to disease activity and cirrhosis. Hepatology 1993; 18: 798-802.
21. 21. Adams DH, Hubscher SG, Shaw J, Rothlein R, Neuberger JM. Intercellular adhesion molecule 1 on liver allografts rejection. Lancet 1989; 11: 1122-5.
22. 22. Nouri-Aria KT, Koskinas J, Tibbs CJ, Portmann BC, Wiliams R. Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: association with disease activity and response to interferon a. Gut 1995; 36: 599-603.
23. 23. Lim AG, Jazrawi RP, Ahmed HA, Levy JH, Zuin M, Douds AC, Maxwell JD, Northfield TC. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: Relationship with disease stage, immune activity and cholestasis. Hepatology 1994; 20: 882-8.
24. 24. Manns M, Gerken G, Kyriatsoulis A, Trautwein C, Reske K, Meyer zum Büschenfelde KH. Two different subtypes of antimitochondrial antibodies are associated with primary biliary cirrhosis: identification and characterisation by radioimmunoassay and immunoblotting. Hepatology 1987; 7: 893-9.
25. 25. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257-60.
26. 26. Hilgers RA. Distribution-free confidence bounds for ROC curves. Meth Inform Med 1991; 30: 96-101.
27. 27. Simpson KJ, Hayes PC. Soluble adhesion molecules in immune mediated liver disease. Gut 1995; 36: 806-8.
28. 28. Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, Eskreis D, Katz S. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989; 10: 414-9.
29. 29. Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1991; 15: 603-8.
30. 30. de Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC. Ursodeoxycholic acid on chronic liver disease. Gut 1991; 32: 1061-5.
31. 31. Mazzella G, Parini P, Bazzoli F, Villanova N, Festi D, Aldini R, Roda A, Cipolla A, Polimeni C, Tonelli D, Roda E. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993; 38: 896-902.
32. 32. Crosignani A, Podda M, Battezzati PM, Bertolini E, Zuin M, Watson D, Setchell KDR. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000-7.
33. 33. Friman S, Persson H, Schersten T, Svanvik J, Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplant Proc 1992; 24: 389-30.
34. 34. Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116: 624-9.
35. 35. Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992; 103: 617-21.
36. 36. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358-64.